Kornimate/medical-research-clean huggingface dataset:
functional electrical stimulation (fes) assisted walking: enhancement of walking function after stroke

Conditions: Stroke

Summary: the purpose of this study is to determine if a form of exercise,known as electrical stimulation can improve walking function and other important health outcomes. the hypothesis is that electrical stimulation can enhance the ability to walk for stroke survivors who are unable to walk on their on their own.

a stroke is a devastating life event, that can result in permanent disability. many people who survive a stroke will experience paralysis on one side of their body. the muscles in one leg may become weaker or stiff to the point that the person can barely walk. functional electrical stimulation (fes) is an intervention that applies short current pulses to muscles and causes them to contract. previous work done by our team has used fes in the spinal cord injured population to help restore functions such as walking and grasping by contracting groups of paralyzed muscles in an orchestrated manner. this study seeks to explore whether a thrice weekly fes-assisted walking intervention for a 8 week period can stimulate or improve walking ability in individuals with severe lower extremity paralysis secondary to a stroke. this will subsequently promote opportunities for enhanced social participation and quality of life i.e. enhanced balance, increased independence of activities of daily living etc. for stroke consumers. comparison: 40 individuals with severe hemiplegia will be randomized to either a thrice weekly control (false) fes training regimen or a thrice weekly intervention (true) fes training regimen. prior to randomization, participants will be stratified according to their ability to ambulate (walk). this study will determine if fes can improve or enhance walking ability associated with stroke after 8 weeks of training, and after 4-month follow-up period.

Eligibility criteria:
inclusion criteria: * hemiplegic stroke at least 12 months prior to joining the study. * age 65 years or greater. * ability to follow instructions and to devote his/her attention to therapy. * ability to understand instructions in english and able to provide informed consent. exclusion criteria: * severe difficulties with attention such that informed consent cannot be obtained, or that safety or communication would be comprised. * ability to walk more that 10 meters during a two minute walk with an average speed greater than 0.8 m/s. * the presence of skin rashes, allergies or bruises where electrodes would be placed. * history of seizures, edema in paralyzed limbs or co-morbidities such as parkinson's disease, cancer or osteoarthritis to be confirmed by attending physiatrist.
topical l. reuteri in children with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study evaluates the safety and efficacy of the probiotic l. reuteri vs control product as an adjuvant for improving the skin appearance of children with mild or moderate atopic dermatitis. all children will receive the standard of care. half of the children will receive topical l. reuteri in emollient, while the other half will receive the standard of care plus control product

ad if a very frequent allergic skin disorders in children. produce a negative significant impact on quality of life and related costs. recently the changes of skin microbiota had been related with inadequate evolution of atopic dermatitis. l. reuteri had been identified with some effect to reduce skin inflammation and help to modulate inflammatory pathways on skin. investigators expect using topical l. reuteri as adjuvant some improvement on skin appearance due to the mode of action previous referenced additionally to some potential changes on microbiome

Eligibility criteria:
inclusion criteria: * children age 1 to 8 years old * atopic dermatitis (ad) according to the criteria of hanifin and rajka * scorad index 15 to 50, inclusive * subjects whose parents or legal representative are willing to sign the informed consent * when the child is 8, he/she must also give consent to participate in the study exclusion criteria: * use of phototherapy for atopic dermatitis * systemic or topic corticosteroids in tthe 30 days prior to the study * immunosuppressive or cytostatic drugs in the 2 months prior to the study * use of probiotics in the 2 weeks prior to the study * other allergic severe disease (asthma, allergic rhinitis) * systemic antibiotics in the four days prior to the study * fever (temperature\> 37.5 °c axillary or equivalent) * pathologies associated with immunodeficiency or cancer processes * dermatological diseases that may hinder the evaluation of atopic dermatitis or require the continued use of topical corticosteroids * subjects for whom any of the studies products are contraindicated according to their technical specifications * subjects who have participated in research studies with any products in the 3 months prior to the trial
oral carnitine for cramps in pregnancy

Conditions: Muscle Cramp

Summary: muscle cramps occur frequently among pregnant women, and few therapeutic options exist. this is a study of oral l-carnitine, a dietary supplement, for the treatment of muscle cramps in pregnancy. our hypothesis is that carnitine will alleviate or eliminate muscle cramps experienced by pregnant women.

muscle cramps occur frequently among pregnant women, and few therapeutic options exist. this is a study of oral l-carnitine, a dietary supplement, for the treatment of muscle cramps in pregnancy. the conceptual basis for this study comes from the fact that carnitine has been used effectively in multiple randomized trials for the treatment of muscle cramps in other carnitine deficient states (such as hemodialysis). in pregnancy, women have decreased serum carnitine concentrations (from decreased intake, increased clearance by the kidney, and increased demands from the fetus). thus, our hypothesis is that carnitine will alleviate or eliminate muscle cramps experienced by pregnant women.

Eligibility criteria:
inclusion criteria: * age 16 or older * gestational age 12 to 33 weeks * occurrence of muscle cramps at least once weekly * ability to tolerate oral l-carnitine * ability / willingness to provide informed consent in english or spanish exclusion criteria: * prior treatment for muscle cramps during this pregnancy * chronic muscle cramps prior to pregnancy * magnesium administration beyond that contained in prenatal vitamins * history of seizures * history of pre-term delivery before 36 weeks gestational age * inability to tolerate oral l-carnitine (e.g. hyperemesis gravidarum) * inability or unwillingness to provide informed consent

Keywords: muscle cramp pregnancy carnitine randomized controlled clinical trials
glucose as a mediator of self-control performances in patients with schizophrenia

Conditions: Schizophrenia

Summary: the research aims to investigate the relationship between self-control ability and blood glucose level in schizophrenic patients. the main purpose of the present study is to explore whether the close relationship of blood glucose and self-regulatory strength observed in healthy individuals, is applicable to schizophrenic patients. more specifically, the current study aims * to investigate whether the exertion of self-control reduces blood glucose, * to examine whether low level of blood glucose deteriorates subsequent self-control performances * to examine whether restoring the glucose level eliminates these impairments, in schizophrenic patients.


Eligibility criteria:
inclusion criteria: * aged 15 or above * dsm-iv diagnosis of schizophrenia, schizoaffective disorder, schizophreniform psychosis, brief psychosis, psychosis nos or delusional disorder * cantonese-speaking chinese * ability to understand the nature of the study and sign informed consent exclusion criteria: * organic brain disorder * known history of intellectual disability * priority follow up (subtarget or target) * all allergic to any sugar or artificial sweeteners * diabetics * physical disability

Keywords: schizophrenia psychotic disorders psychoses
treatment of bacterial vaginosis with oral tinidazole

Conditions: Bacterial Vaginosis

Summary: the purpose of this study is to confirm the safety and efficacy of oral tinidazole for the treatment of bacterial vaginosis.

tinidazole is a second-generation nitroimidazole i.e. an updated form of the standard drug used to treat bacterial vaginosis (metronidazole). two dosing regimens are being compared to placebo to treat bacterial vaginosis, one of the most common vaginal infections.

Eligibility criteria:
inclusion criteria: clinical and microbiological diagnosis of bacterial vaginosis - exclusion criteria: other sexually transmitted disease -
remote ischemic preconditioning in ad hoc percutaneous coronary interventions

Conditions: Coronary Artery Disease

Summary: elective percutaneous coronary intervention (pci) is associated with troponin release in approximately one third of cases. myocardial necrosis may result from downstream embolization of atheromatous material, coronary side-branch occlusion and may involve ischemia/reperfusion injury. the investigators hypothesized that a single remote ischemic preconditioning cycle would reduce peri-procedural troponin release.

elective percutaneous coronary intervention (pci) is associated with troponin release in approximately one third of cases, which is a sensitive and specific marker of myocyte necrosis. myocardial necrosis may result from downstream embolization of atheromatous material, coronary side-branch occlusion and may involve ischemia/reperfusion injury. a number of studies have demonstrated that procedure-related troponin release is associated with subsequent cardiovascular events and a worst prognosis, especially in those patients with the most marked elevation in troponin concentration. recently, 3 cycles of 5-minute ischemia followed by 5-minute reperfusion of the upper extremities were shown to reduce troponin release in elective pci. however, this ischemic preconditioning (ipc) protocol requires 30 minutes and is of limited use in the context of pci at the time of initial cardiac catheterization (ad hoc coronary intervention). since experimental evidence suggests that ipc is a graded than an "all-or-nothing" phenomenon, and even a short, single ipc cycle may have protective effects in the myocardium, the investigators hypothesized that patients undergoing ad hoc coronary intervention would have reduced peri-procedural troponin release if subjected to a single, remote ipc cycle, between diagnostic catheterization and coronary intervention.

Eligibility criteria:
inclusion criteria: * patients with a significant stenosis as documented in coronary angiography eligible for pci * patients ≥ 18 of age and able to give informed consent exclusion criteria: * severe comorbidity (estimated life expectancy \<6 months) * use of nicorandil or glibenclamide * elevated baseline ctni before pci * renal disease as documented by serum creatinine before pci * lvef\<35%

Keywords: percutaneous coronary intervention remote ischemic preconditioning
virtual reality as anxiety management tool for preparing children for mr exam

Conditions: Claustrophobia

Summary: the access to mri examination is limited due to the duration of the acquisitions, the noise and the narrow patient space of the device. a child can, therefore, be anxious, less cooperative and move more during the acquisition, affecting the quality of the examination and the medical diagnosis. general anesthesia or sedation, may be considered to obtain diagnostic quality examinations. our hypothesis is that a scenario as close as possible to reality to prepare children before the mr exam could reduce their anxiety, improve the quality of the exams and reduce its duration. the purpose of this study is to evaluate the effect of virtual reality on mri exam preparation to reduce the anxiety of children (aged from 6 to 12 years) who are referred to their first mri exam, as compared to the current practice.


Eligibility criteria:
inclusion criteria: * child from 6 to 12 years old, * child who will have an mri for the first time, * outpatient child, * child dependent on a parent affiliated to or beneficiary of a social security scheme, * child who has received age-appropriate information on the organization of the research, * child whose parents (or the only parent present with parental authority) have been fully informed about the organization of the research and have signed informed consent. exclusion criteria: * conditions that not allow the realization of a virtual mri sceanrio or not allow to respond the scales (epilepsy, mental disorders, language, ...), * child with a contraindication to performing an mri, * child who has benefited from another mri simulation system before ("irm en jeu" for instance) * child's opposition to participate.
gp2013 in japanese patients with cd20 positive low tumor burden indolent b-cell non-hodgkin's lymphoma

Conditions: Indolent B-cell Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to evaluate safety and pharmacokinetic of gp2013 in japanese patients with cd20 positive low tumor burden indolent b-cell nhl under weekly dosing schedule.


Eligibility criteria:
inclusion criteria: * patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma. * patient with at least one measurable lesion. * patient with ecog performance status 0 or 1. exclusion criteria: * patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy. * patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy. * patient who has mab therapy other than rituximab as prior line of therapy. * patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal). * patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: gp2013 japanese indolent b-cell non-hodgkin's lymphoma biosimilar cd20 gp13-101
nbi for identifying resection margin status in gastric cancer

Conditions: Gastric Cancer

Summary: as the proportion of early gastric cancer has been steadily increased in korea, so has function-preserving surgery. the function preserving surgery is characterized by the minimized extent of gastrectomy, so this implies that bilateral margins are getting shorter than those of standard gastrectomies. currently, there is only one way to identify resection margin status in gastric cancer, 'frozen biopsy'. however, it is labor-intensive and time-consuming procedure. in addition, the results rely on the pathologist's expertise, thereby it showed limitation of its accuracy; high false negative rate of signet ring cell carcinoma was reported in a previous study. recently, many studies on magnifying endoscopy with narrow band imaging(nbi) demonstrated that this emerging technique is useful to identify the gastric tumor margin more clearly in vivo, compared with conventional indigocarmine chromoendoscopy. so it was hypothesized that nbi may allow reliable delineation of tumor and identification of resection margin status in the specimen after gastrectomy for gastric cancer.

1. tumor delineation and identification of resection margin: after specimen delivery from the abdomen, frozen biopsy is performed before checking tumor margin. after inspection with nbi, the tumor margin is marked with electrocauterization. the tumor size and the lengths of both resection margins are evaluated using a ruler. 2. pathologic examination: the specimen is sliced as 4mm interval paralleled to the markings. tumor size, the status of both resection margins, and microvessel density are evaluated under the 200 magnified view.

Eligibility criteria:
inclusion criteria: * the patient from over 20 to under 90 years * the patient who is diagnosed as gastric cancer clinically by endoscopy or computed tomography * the patient who is informed and consent about the purpose and contents of this study prior to the participation in this study exclusion criteria: * the patient who shows far advanced gastric cancer preoperatively or intraoperatively * the patient with previous medical history of other treatment for gastric caner such as endoscopic resection, chemotherapy, radiation, immunotherapy, and so on

Keywords: stomach neoplasm endoscopy narrow band imaging
is hepatitis b surface antigen (hb s ag) enough alone as a screening test before immunosuppressive therapies?

Conditions: Hepatitis B

Summary: hepatitis b virus (hbv) infection is a challenging health problem. according to the world health organization, an estimated 240 million individuals (3.7%) suffered from chronic hbv infection worldwide. after acute hepatitis b virus (hbv) infection, the disappearance of hepatitis b surface antigen (hbsag) had generally been believed to signify viral elimination. however, it now becomes clear that those subjects may have occult hbv infection which is defined as the presence of hbv dna in the liver in the absence of hbsag in the serum. occult hbv infection usually accompanies antibody against hepatitis b core antigen (anti-hbc) and/or antibody against hbsag (anti-hbs), but some cases might not have these serological markers (seronegative occult hbv infection) .

in a recent systematic review, nearly 40% of hbsag carriers and 5% of antihbc-positive but hbsag-negative patients developed hbvr during tnf inhibitor therapy. considering the lifelong use of multiple antirheumatic drugs, we need more specific guidelines for the management of rheumatic disease patients who are scheduled to receive biological and/or non-biological dmards.

Eligibility criteria:
inclusion criteria: * • any patients with rheumatic disease with hepatitis b surface antigen negative. exclusion criteria: * • overt co-morbid condition. * any malignancy e.g. hcc
virtual nephrologist pilot

Conditions: Chronic Kidney Disease(CKD)

Summary: to develop, pilot, and refine a virtual healthcare agent that will educate patients with advanced chronic kidney disease and their caregivers about kidney transplantation.

over 35 million americans endure the burdens of chronic kidney disease (ckd). black americans face particularly high rates of ckd due to environmental and genetic factors, including systemic racism and inadequate access to specialty providers and effective therapies. the optimal management of advanced ckd poses many challenges for patients, especially those with low health literacy, because of the complexity of medical management and treatment options. for many patients with advanced ckd, pursuing kidney transplantation has major advantages. compared to chronic dialysis, kidney transplantation improves quality of life and length of life, and offers greater capacity to participate in important activities such as employment. unfortunately, many patients do not gain sufficient information about kidney transplant or have misconceptions and fears about transplant. this knowledge gap exists in part because many patients have limited access to nephrology care and due to time constraints and ineffective education during nephrology visits. new media technologies can address this need by enabling patients to interact with a virtual health care assistant that both empowers patients to direct the communication toward their own information needs and communicates with patients using language and norms that are comfortable. we will develop a virtual healthcare assistant to interact with, educate and counsel patients and their caregivers about kidney transplantation. the tool will provide content developed by the national kidney foundation, the leading patient-facing organization focused on kidney disease. informed by patient partnerships, the tool will address in particular the needs and concerns of black americans with kidney disease.

Eligibility criteria:
inclusion criteria: * 18 y/o able to provide consent * advanced ckd * english speaking * penn medicine patient exclusion criteria: * vulnerable populations

Keywords: ckd transplantation virtual healthcare agent nkf
response to medication registry

Conditions: Adverse Drug Events

Summary: to create a registry/database of patients who either have taken drugs that treat cardiovascular conditions or that have presented with cardiovascular symptoms that may be related to medication.

to create a registry/database of patients who either have taken drugs that treat cardiovascular conditions or that have presented with cardiovascular symptoms that may be related to medication. potential enrollees are those receiving (presently or in the past) the medicine(s) of interest. subjects will be identified from computerized intermountain healthcare records. patients receiving a drug of interest, both with and without an ade will be enrolled in approximately equal numbers. outpatients will be contacted by mail and invited to participate. interested subjects will be instructed to return the enclosed response card with their intent indicated. the registry coordinator will contact interested subjects and the project will be explained. willing participants will be enrolled either in person or via mail with the assistance of the project coordinator. persons presenting in person for enrollment will be given the choice of venipuncture or buccal swab for sample collection for dna extraction. in all cases informed consent will be obtained before collecting samples.

Eligibility criteria:
inclusion criteria: * the patient must be \> 18 years of age. * the patient or legally authorized representative must sign a written informed consent, prior to sample collection, using a form that is approved by the local institutional review board. * the patient must have taken a medication of interest or have presented with a cardiovascular symptom possibly related to medication. the current medications of interest are as follows: * ace inhibitors * arbs * aldosterone antagonists * alpha-andrenergic agonists * anticoagulants * b-type natriuretic peptides * beta-blockers * calcium channel blockers * cardiac glycosides * antiarrhythmics * combination drugs * diuretics * electrolyte/mineral replacements * lipid-lowering medications * positive inotropes * vasodilators/nitrates * statins * antibiotics * anthrocyclines exclusion criteria: * there are no exclusion criteria for this registry.